Table 2.
Adverse events
| Placebo group (n=54) | pGM169/GL67A group (n=62) | |
|---|---|---|
| Lower airway respiratory symptoms | 7·9 | 9·0 |
| Gastrointestinal symptoms | 2·1 | 1·8 |
| Fever or flu-like symptoms | 1·1 | 1·4 |
| Headache | 1·2 | 1·1 |
| Upper airway symptoms | 2·3 | 3·4 |
| Elevated liver function tests | 0·3 | 0·4 |
| Haematuria | 0·2 | 0·2 |
| Isolated raised inflammatory markers | 0·8 | 0·7 |
| Other | 3·2 | 3·3 |
| Total | 19·1 | 21·2 |
Data are mean number of times the respective symptom was experienced by each patient during the trial. Values were calculated by dividing the total number of the relevant adverse event by the total number of relevant patients in that group.